Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Quick facts
Phase 3 pipeline
- DAG181 · Oncology
DAG181 is a humanized monoclonal antibody that targets and blocks PD-L1, enhancing anti-tumor immune responses by releasing the PD-1/PD-L1 checkpoint inhibition. - TG-2349 · Diabetes
TG-2349 is a small molecule drug that targets the SGLT2 receptor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. portfolio CI brief
- Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. pipeline updates RSS
Frequently asked questions about Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
What is Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.'s pipeline?
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include DAG181, TG-2349.
Related
- Sector hub: All tracked pharma companies